FDA approves Rapivab (peramivir injection) extending its availability for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older.- BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals, Inc. announced that the FDA has approved a supplemental New Drug Application for Rapivab (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor, extending its availability for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days. The pediatric approval was based on the interim analysis of an ongoing pediatric clinical study. Those results will be presented at the upcoming ID Week 2017 meeting in San Diego.
This approval represents the first new influenza antiviral for pediatric use in over 10 years.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins